Related Experiment Video
Updated: Sep 2, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
New Perspectives on Antimicrobial Agents: Maribavir.
Virginie Halpern-Cohen1, Emily A Blumberg1
1Department of Medicine, Division of Infectious Diseases, Ruth and Raymond Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Maribavir offers a new oral treatment for refractory cytomegalovirus (CMV) infections post-transplant. It shows efficacy and a better safety profile than older therapies for resistant CMV disease.
Area of Science:
- Virology
- Pharmacology
- Transplantation Medicine
Background:
- Post-transplant cytomegalovirus (CMV) infection/disease is a significant complication.
- Existing therapies for refractory CMV are limited by resistance and side effects.
- Maribavir represents a novel therapeutic option for managing resistant CMV.
Purpose of the Study:
- To review the chemistry and clinical pharmacology of maribavir.
- To summarize clinical efficacy, safety, and tolerability data of maribavir.
- To discuss resistance patterns associated with maribavir therapy.
Main Methods:
- Review of published clinical trial data and scientific literature.
- Analysis of maribavir's mechanism of action and pharmacokinetic properties.
- Evaluation of safety, efficacy, and resistance data from clinical studies.
Main Results:
- Maribavir is an oral benzimidazole riboside with potent, selective anti-CMV activity.
- It demonstrates efficacy in treating refractory CMV infections, including those with genotypic resistance.
- Maribavir exhibits a more favorable safety profile compared to traditional anti-CMV agents.
Conclusions:
- Maribavir is approved for refractory CMV infections in transplant recipients.
- Its novel mechanism of action provides an alternative for resistant cases.
- The drug offers a promising therapeutic advance with improved tolerability.
Related Concept Videos
Antimicrobial Effectiveness
Antibiotic Selection
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Development of Antibiotic Resistance
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Subviral Agents

